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The abstract of this work was presented at the American Heart Association\'s Scientific Sessions, November 11 to 15, 2017, in Anaheim, CA.

Clinical PerspectiveWhat Is New?Prior studies have demonstrated the safety of nicotine replacement therapy among smokers with stable coronary heart disease in outpatient settings; this study is the first to demonstrate that nicotine replacement therapy appears safe among smokers hospitalized for treatment of coronary heart disease, even when started within the first or second hospital day, including among critically ill patients in the intensive care unit.What Are the Clinical Implications?Although some caution is always appropriate, our findings should allow clinicians to confidently prescribe nicotine replacement therapy in the hospital to treat withdrawal, reduce cravings, and promote smoking cessation after discharge without concerns for inducing major adverse events.

 {#jah33446-sec-0008}

The immediate cardiovascular effects of nicotine use can include a short‐term increase in heart rate by 10 to 15 beats per minute and an increase in systolic blood pressure of up to 5 to 10 mm Hg.[1](#jah33446-bib-0001){ref-type="ref"} Consequently, when nicotine replacement therapy (NRT) was first introduced as a treatment to aid smoking cessation, clinicians worried that NRT would increase myocardial demand and provoke myocardial infarction (MI).[1](#jah33446-bib-0001){ref-type="ref"} This concern was later refuted by 3 randomized controlled trials that demonstrated that NRT was safe in smokers with coronary heart disease (CHD), but only in a stable outpatient setting and not among patients hospitalized with CHD.[2](#jah33446-bib-0002){ref-type="ref"}, [3](#jah33446-bib-0003){ref-type="ref"}, [4](#jah33446-bib-0004){ref-type="ref"} However, recognizing that there were still unresolved concerns about the safety of NRT in the hospital, the most recent US Public Health Service Clinical Practice Guidelines (2008) advise that NRT should generally not be used within 2 weeks of an MI.[5](#jah33446-bib-0005){ref-type="ref"}

However, over the past decade, several small observational studies have suggested that NRT use may be safe in the medical intensive care unit,[6](#jah33446-bib-0006){ref-type="ref"} during an admission for acute coronary syndrome,[7](#jah33446-bib-0007){ref-type="ref"} or at the time of hospital discharge,[8](#jah33446-bib-0008){ref-type="ref"} although another study raised concerns among patients undergoing cardiac surgery.[9](#jah33446-bib-0009){ref-type="ref"} However, no large, well‐powered study has examined this question, and none has examined the use of NRT within the first few days of an MI. In addition, recent guidelines from the American College of Cardiology/American Heart Association and the US Preventive Services Task Force provide no recommendations on this issue. Consequently, substantial doubt remains in the minds of many clinicians, and this barrier almost certainly contributes to the low use (20%) of NRT among patients hospitalized with MI.[10](#jah33446-bib-0010){ref-type="ref"}, [11](#jah33446-bib-0011){ref-type="ref"} Furthermore, because the majority of relapse happens within 2 weeks after hospital discharge,[12](#jah33446-bib-0012){ref-type="ref"} it is essential to begin treatment while patients are hospitalized, because this promotes greater NRT use[13](#jah33446-bib-0013){ref-type="ref"} and aids in smoking cessation.[14](#jah33446-bib-0014){ref-type="ref"}

We, therefore, took advantage of data from a large hospital network and evaluated the short‐term safety of NRT among patients admitted for treatment of CHD. We hypothesized that, consistent with prior smaller studies, NRT would have no association with changes (either beneficial or harmful) in short‐term outcomes, even when used within the first few days of an MI or revascularization procedure.

Methods {#jah33446-sec-0009}
=======

Design and Setting {#jah33446-sec-0010}
------------------

We conducted a retrospective cohort study at 282 US hospitals that participated in the Premier Healthcare Inpatient Database Alliance (Premier Inc.) in the year 2014. This database has been previously described.[15](#jah33446-bib-0015){ref-type="ref"} In brief, Premier is a geographically and structurally diverse group of US hospitals that captures ≈15% to 20% of inpatient US hospitalizations. Unlike administrative databases that contain only basic sociodemographic, diagnostic, and procedure codes assigned at the time of discharge, Premier also contains date‐stamped hospital service codes for every medication, procedure, diagnostic test, and therapeutic service. Because the data are fully deidentified, the Institutional Review Board at Baystate Medical Center determined that this study did not meet the federal definition of human subject\'s research and waived the requirement for informed consent.

Data Sharing Statement {#jah33446-sec-0011}
----------------------

The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. The authors do not determine access to the Premier database. However, researchers interested in reproducing our results may be able to obtain database access directly from Premier Inc.

Population, Characteristics, and Treatments {#jah33446-sec-0012}
-------------------------------------------

We included smokers, defined on the basis of an *International Classification of Diseases, Ninth Revision, Clinical Modification* (*ICD‐9‐CM*) diagnosis code of 305.1, which has previously been validated and found to have fair sensitivity but high specificity for active smoking.[16](#jah33446-bib-0016){ref-type="ref"} Among these patients, we evaluated those who were admitted with a principal diagnosis of MI (*ICD‐9* 410.x) or received percutaneous coronary intervention (PCI; *ICD‐9* 36.06, 36.07, or 36.09) or coronary artery bypass graft (CABG) surgery (*ICD‐9* 36.1x). We grouped patients into 3 mutually exclusive categories: (1) those with medically managed acute MI, (2) patients who underwent PCI with or without MI, and (3) those who received CABG with or without MI or PCI. This division allowed us to do straightforward and easily interpretable statistical modeling within groups with similar characteristics and outcomes, rather than attempting to combine significantly different populations and outcomes. For patients admitted more than once in the year, we randomly selected a single admission for inclusion in this analysis to allow unbiased assessment of inpatient mortality.

To ensure that NRT exposure preceded outcomes assessment, we included only patients who received NRT in the first 2 days of hospitalization and excluded any patients with death or hospital discharge during the first 2 days. This exposure time frame ensured that all patients were hospitalized for \>24 hours and also ensured that nicotine levels were therapeutic, because the nicotine patch achieves peak concentration within 6 hours.[17](#jah33446-bib-0017){ref-type="ref"} This also allowed us to evaluate most patients who received NRT, while still allowing adequate observation time for in‐hospital mortality. This exclusion also eliminated elective hospital admissions for planned and uncomplicated PCI, during which patients were only hospitalized for 1 night and would be unlikely to have unstable CHD. More important, because length of stay (LOS) is counted by the number of nights spent in the hospital, LOS=1 is equivalent to 2 days and 1 night in the hospital. Similarly, LOS=3 is equivalent to 4 days and 3 nights spent in the hospital.

We recorded demographic data, such as age, sex, race/ethnicity, and insurance status, for each patient. We included 29 individual chronic comorbidity indicators on the basis of methods developed by Elixhauser et al[18](#jah33446-bib-0018){ref-type="ref"} using the software provided by the Healthcare Costs and Utilization Project of the Agency for Healthcare Research and Quality, and also calculated a combined comorbidity score, as described by Gagne et al.[19](#jah33446-bib-0019){ref-type="ref"} In addition, we included hospital characteristics, such as size, teaching status, urban or rural population served, and census region.

Because NRT has been associated with increased blood pressure and heart rate, it may have been considered contraindicated among patients who were hemodynamically unstable or who had significant hypertension. Accordingly, we carefully separated *ICD‐9* codes for hypertension into 2 categories of complicated and uncomplicated so that we could track and adjust for potential contraindications to the use of NRT among those with more severe hypertension or hypertensive urgency. We consider hypertension to be uncomplicated when given an *ICD‐9* code of 401.1, 401.9, 642.00, 642.03, or 642.04 and complicated when given a code of 401.0, 437.2, 642.2x (x=0, 1, 2, 3, 4), 402.00, 402.10, 402.90, 405.09, 405.19, 405.99, 402.01, 402.11, 402.91, 403.00, 403.10, 403.90, 405.01, 405.11, 405.91, 642.10, 642.11, 642.12, 642.13, 642.14, 403.01, 403.11, 403.91, 404.00, 404.10, 404.90, 404.01, 404.11, 404.91, 404.02, 404.12, 404.92, 404.03, 404.13, 404.93, 642.70, 642.71, 642.72, 642.73, 642.74, 642.90, 642.91, 642.92, 642.93, or 642.94. Similarly, we also tracked the use of several critical care therapies in the first 2 days of hospitalization and included them as baseline characteristics. This included recording the use of inotropes, vasopressors, invasive and noninvasive ventilation, intra‐aortic balloon pump, and/or arterial line, as has previously been done.[20](#jah33446-bib-0020){ref-type="ref"}, [21](#jah33446-bib-0021){ref-type="ref"} We also included location in an intensive care or intermediate care unit as a marker of illness severity. Together, these factors helped us to identify high‐risk subjects who might not be prescribed NRT because of hemodynamic concerns and were important in ensuring that the propensity score adjusted for available baseline differences.

Using pharmacy charges, we identified patients who were dispensed any form of NRT, including the nicotine patch, gum, lozenge, and inhaler. We excluded patients who received varenicline or bupropion at any point in the hospitalization because these medications were used only rarely[10](#jah33446-bib-0010){ref-type="ref"} and have separate safety concerns. We measured the average daily dose of nicotine patch (the most common therapy), but were unable to track how often the other ad libitum NRT products were used.

Outcome Measures {#jah33446-sec-0013}
----------------

We evaluated 3 primary outcomes: all‐cause inpatient mortality, total hospital LOS, and 1‐month readmission among survivors. To ensure that any outcomes occurred after exposure to NRT and to avoid immortal time bias, we excluded patients with a hospital LOS=1 (equivalent to 2 days.). We also included total hospital cost as an outcome of interest because this is a useful marker to overall resource use.[22](#jah33446-bib-0022){ref-type="ref"} Because cost and LOS were highly skewed, we winsorized both outcomes at the 1st or 99th percentile, depending on their distribution.[23](#jah33446-bib-0023){ref-type="ref"} Because the Premier database is deidentified, readmission was known only if it occurred to the same hospital as the primary event, and only the month of readmission was recorded. This factor may have reduced the incidence of this outcome, because potential readmission to other hospitals was unknown.

Statistical Analysis {#jah33446-sec-0014}
--------------------

We calculated descriptive statistics for patients and hospitals using percentages for categorical variables and means, SDs, or quartiles (median and 25th and 75th percentiles) for continuous variables. We compared characteristics of patients with and without NRT treatment using absolute standardized differences rather than *P* values (Table [1](#jah33446-tbl-0001){ref-type="table"}, footnote).[24](#jah33446-bib-0024){ref-type="ref"}, [25](#jah33446-bib-0025){ref-type="ref"} Within each patient diagnosis group, we examined the association between receipt of NRT and unadjusted outcomes using generalized estimating equations models to account for clustering of patients within hospitals, using logit link for binary outcomes and identity link for continuous outcomes. To obtain stable estimates from hierarchical models, we excluded hospitals with \<10 eligible patients in each patient group.

###### 

Patient Characteristics and Unadjusted Outcomes in All Cohorts

  Description                                           PCIMI                                                                         
  ----------------------------------------------------- ------------------------- ------------------------- ------------------------- ------------------------------------------------------
  Patients                                              16 785 (100)              13 716 (81.7)             3069 (18.3)               
  Group                                                                                                                               
  PCI                                                   4169 (24.8)               3362 (24.5)               807 (26.3)                
  MI+PCI                                                12 616 (75.2)             10 354 (75.5)             2262 (73.7)               4.1
  Age, y                                                                                                                              
  Median (IQR)                                          57 (50--64)               57 (51--65)               56 (49--62)               
  Mean (SD)                                             57.4 (10.5)               57.8 (10.6)               55.9 (9.7)                18.3
  Sex                                                                                                                                 
  Male                                                  11 718 (69.8)             9617 (70.1)               2101 (68.5)               
  Female                                                5067 (30.2)               4099 (29.9)               968 (31.5)                3.6
  Race/ethnicity                                                                                                                      16.9
  White                                                 12 155 (72.4)             9775 (71.3)               2380 (77.5)               
  Black                                                 1889 (11.3)               1623 (11.8)               266 (8.7)                 
  Hispanic                                              840 (5)                   745 (5.4)                 95 (3.1)                  
  Other                                                 1901 (11.3)               1573 (11.5)               328 (10.7)                
  Marital status                                                                                                                      7.7
  Married                                               7200 (42.9)               5920 (43.2)               1280 (41.7)               
  Single                                                7544 (44.9)               6081 (44.3)               1463 (47.7)               
  Other                                                 2041 (12.2)               1715 (12.5)               326 (10.6)                
  Insurance payer                                                                                                                     18
  Medicare                                              5673 (33.8)               4748 (34.6)               925 (30.1)                
  Medicaid                                              2641 (15.7)               2006 (14.6)               635 (20.7)                
  Managed care                                          4410 (26.3)               3603 (26.3)               807 (26.3)                
  Commercial‐indemnity                                  1140 (6.8)                961 (7)                   179 (5.8)                 
  Self‐pay                                              1864 (11.1)               1504 (11)                 360 (11.7)                
  Other                                                 1057 (6.3)                894 (6.5)                 163 (5.3)                 
  Gagne combined comorbidity score                                                                                                    
  Median (IQR)                                          0 (0--2)                  0 (0--2)                  0 (0--2)                  
  Mean (SD)                                             1.1 (2.2)                 1.1 (2.2)                 1.1 (2.1)                 1.4
  Comorbidities                                                                                                                       
  Congestive heart failure                              3352 (20)                 2761 (20.1)               591 (19.3)                2.2
  Valvular disease                                      1371 (8.2)                1129 (8.2)                242 (7.9)                 1.3
  Pulmonary circulation disease                         524 (3.1)                 431 (3.1)                 93 (3)                    0.7
  Peripheral vascular disease                           2152 (12.8)               1754 (12.8)               398 (13)                  0.5
  Hypertension with complications                       2066 (12.3)               1738 (12.7)               328 (10.7)                6.2
  Hypertension without complications                    10 181 (60.7)             8273 (60.3)               1908 (62.2)               3.8
  Paralysis                                             159 (0.9)                 137 (1)                   22 (0.7)                  3.1
  Other neurological disorders                          692 (4.1)                 552 (4)                   140 (4.6)                 2.7
  Chronic pulmonary disease                             4653 (27.7)               3593 (26.2)               1060 (34.5)               18.2
  Diabetes mellitus                                     5270 (31.4)               4353 (31.7)               917 (29.9)                4
  Hypothyroidism                                        1076 (6.4)                908 (6.6)                 168 (5.5)                 4.8
  Renal failure                                         1475 (8.8)                1266 (9.2)                209 (6.8)                 8.9
  Liver disease                                         272 (1.6)                 202 (1.5)                 70 (2.3)                  6
  AIDS                                                  37 (0.2)                  30 (0.2)                  7 (0.2)                   0.2
  Lymphoma                                              47 (0.3)                  43 (0.3)                  4 (0.1)                   3.9
  Metastatic cancer                                     58 (0.3)                  48 (0.3)                  10 (0.3)                  0.4
  Solid tumor without metastasis                        139 (0.8)                 119 (0.9)                 20 (0.7)                  2.5
  Rheumatoid arthritis/collagen vascular                310 (1.8)                 258 (1.9)                 52 (1.7)                  1.4
  Obesity                                               3178 (18.9)               2589 (18.9)               589 (19.2)                0.8
  Weight loss                                           260 (1.5)                 220 (1.6)                 40 (1.3)                  2.5
  Chronic blood loss anemia                             66 (0.4)                  59 (0.4)                  7 (0.2)                   3.5
  Deficiency anemias                                    1504 (9)                  1279 (9.3)                225 (7.3)                 7.2
  Alcohol abuse                                         1190 (7.1)                881 (6.4)                 309 (10.1)                13.3
  Drug abuse                                            1136 (6.8)                880 (6.4)                 256 (8.3)                 7.4
  Psychoses                                             581 (3.5)                 449 (3.3)                 132 (4.3)                 5.4
  Depression                                            1520 (9.1)                1150 (8.4)                370 (12.1)                12.1
  Early treatments/procedures (day 0, 1, or 2)                                                                                        
  ICU/CVICU/intermediate care                           9675 (57.6)               7989 (58.2)               1686 (54.9)               6.7
  Vasodilators                                          6508 (38.8)               5315 (38.7)               1193 (38.9)               0.2
  NIV                                                   529 (3.1)                 431 (3.1)                 98 (3.2)                  0.3
  IMV                                                   982 (5.8)                 878 (6.4)                 104 (3.4)                 14
  Vasopressors                                          1944 (11.6)               1654 (12.1)               290 (9.4)                 8.4
  Arterial line                                         302 (1.8)                 268 (1.9)                 34 (1.1)                  6.9
  IABP                                                  478 (2.8)                 428 (3.1)                 50 (1.6)                  9.8
  Inotropes                                             872 (5.2)                 775 (5.6)                 97 (3.2)                  12.1
  Hospital size, beds                                                                                                                 10.8
  ≤200                                                  1873 (11.2)               1536 (11.2)               337 (11)                  
  201--400                                              5717 (34.1)               4545 (33.1)               1172 (38.2)               
  ≥401                                                  9195 (54.8)               7635 (55.7)               1560 (50.8)               
  Rural/urban                                                                                                                         0.7
  Urban                                                 14 309 (85.2)             11 791 (86.0)             2518 (82.1)               
  Rural                                                 2476 (14.7)               1925 (14.0)               551 (17.9)                
  Hospital region                                                                                                                     5.7
  Northeast                                             2623 (15.6)               2104 (15.3)               519 (16.9)                
  Midwest                                               3256 (19.4)               2636 (19.2)               620 (20.2)                
  West                                                  1163 (6.9)                965 (7.0)                 198 (6.4)                 
  South                                                 9743 (58.0)               8011 (58.4)               1732 (56.4)               
  Teaching status                                                                                                                     2.5
  Nonteaching                                           8726 (52.0)               7052 (51.4)               1674 (54.5)               
  Teaching                                              8059 (48.0)               6664 (48.6)               1395 (45.4)               
  Outcomes---PCIMI Group                                                                                                              GEE *P* Value[a](#jah33446-note-0003){ref-type="fn"}
  In‐hospital mortality                                 246 (1.5)                 231 (1.7)                 15 (0.5)                  \<0.001
  LOS, d                                                                                                                              
  Median (IQR)                                          3 (2--4)                  3 (2--4)                  3 (2--4)                  
  Mean (SD)                                             3.8 (3.7)                 3.9 (3.9)                 3.6 (3.1)                 
  Winsorized at 99th percentile, mean (SD)                                        3.8 (3.0)                 3.6 (2.6)                 0.002
  Winsorized at 99th percentile, survivors, mean (SD)   3.7 (2.8)                 3.7 (2.9)                 3.5 (2.5)                 
  All‐cause readmission among survivors (≈1 mo)         1490 (9.0)                1210 (9)                  280 (9.2)                 0.79
  Cost, US \$                                                                                                                         
  Median (IQR)                                          14 705 (11 258--20 336)   14 768 (11 235--20 620)   14 498 (11 362--19 114)   
  Mean (SD)                                             18 427 (15 025)           18 681 (15 701)           17 295 (11 463)           
  Winsorized at 1st and 99th percentiles, mean (SD)                               18 208 (11 746)           17 110 (9905)             \<0.001

  Description                                           CABG                                                                          
  ----------------------------------------------------- ------------------------- ------------------------- ------------------------- ------------------------------------------------------
  Patients                                              6155 (100)                5177 (84.1)               978 (15.9)                
  Principle diagnosis of myocardial infarction          2337 (38.0)               1914 (37.0)               423 (43.2)                12.8
  Age, y                                                                                                                              
  Median (IQR)                                          60 (54--67)               61 (54--67)               58 (52--64)               
  Mean (SD)                                             60.2 (9.9)                60.6 (10.0)               57.9 (9.1)                28.5
  Sex                                                                                                                                 
  Male                                                  4649 (75.5)               3915 (75.6)               734 (75.1)                
  Female                                                1506 (24.5)               1262 (24.4)               244 (24.9)                1.3
  Race/ethnicity                                                                                                                      19.3
  White                                                 4672 (75.9)               3887 (75.1)               785 (80.3)                
  Black                                                 550 (8.9)                 497 (9.6)                 53 (5.4)                  
  Hispanic                                              274 (4.5)                 246 (4.8)                 28 (2.9)                  
  Other                                                 659 (10.7)                547 (10.6)                112 (11.5)                
  Marital status                                                                                                                      13.8
  Married                                               2898 (47.1)               2449 (47.3)               449 (45.9)                
  Single                                                2526 (41)                 2083 (40.2)               443 (45.3)                
  Other                                                 731 (11.9)                645 (12.5)                86 (8.8)                  
  Insurance payer                                                                                                                     25.8
  Medicare                                              2533 (41.2)               2182 (42.1)               351 (35.9)                
  Medicaid                                              931 (15.1)                707 (13.7)                224 (22.9)                
  Managed care                                          1432 (23.3)               1230 (23.8)               202 (20.7)                
  Commercial‐indemnity                                  483 (7.8)                 412 (8)                   71 (7.3)                  
  Self‐pay                                              427 (6.9)                 347 (6.7)                 80 (8.2)                  
  Other                                                 349 (5.7)                 299 (5.8)                 50 (5.1)                  
  Gagne combined comorbidity score                                                                                                    
  Median (IQR)                                          2 (0--4)                  2 (0--4)                  2 (0--4)                  
  Mean (SD)                                             2.3 (2.4)                 2.2 (2.5)                 2.3 (2.5)                 3.2
  Comorbidities                                                                                                                       
  Congestive heart failure                              1654 (26.9)               1392 (26.9)               262 (26.8)                0.2
  Valvular disease                                      1062 (17.3)               903 (17.4)                159 (16.3)                3.2
  Pulmonary circulation disease                         342 (5.6)                 288 (5.6)                 54 (5.5)                  0.2
  Peripheral vascular disease                           1409 (22.9)               1183 (22.9)               226 (23.1)                0.6
  Hypertension with complications                       928 (15.1)                773 (14.9)                155 (15.8)                2.5
  Hypertension without complications                    4195 (68.2)               3523 (68.1)               672 (68.7)                1.4
  Paralysis                                             103 (1.7)                 91 (1.8)                  12 (1.2)                  4.4
  Other neurological disorders                          291 (4.7)                 240 (4.6)                 51 (5.2)                  2.7
  Chronic pulmonary disease                             2726 (44.3)               2180 (42.1)               546 (55.8)                27.7
  Diabetes mellitus                                     2586 (42)                 2170 (41.9)               416 (42.5)                1.3
  Hypothyroidism                                        459 (7.5)                 385 (7.4)                 74 (7.6)                  0.5
  Renal failure                                         751 (12.2)                642 (12.4)                109 (11.1)                3.9
  Liver disease                                         146 (2.4)                 111 (2.1)                 35 (3.6)                  8.6
  AIDS                                                  8 (0.1)                   5 (0.1)                   3 (0.3)                   4.7
  Lymphoma                                              24 (0.4)                  19 (0.4)                  5 (0.5)                   2.2
  Metastatic cancer                                     6 (0.1)                   6 (0.1)                                             4.8
  Solid tumor without metastasis                        60 (1)                    51 (1)                    9 (0.9)                   0.7
  Rheumatoid arthritis/collagen vascular                88 (1.4)                  73 (1.4)                  15 (1.5)                  1
  Obesity                                               1488 (24.2)               1250 (24.1)               238 (24.3)                0.4
  Weight loss                                           202 (3.3)                 170 (3.3)                 32 (3.3)                  0.1
  Chronic blood loss anemia                             74 (1.2)                  66 (1.3)                  8 (0.8)                   4.5
  Deficiency anemias                                    1100 (17.9)               911 (17.6)                189 (19.3)                4.5
  Alcohol abuse                                         517 (8.4)                 383 (7.4)                 134 (13.7)                20.6
  Drug abuse                                            340 (5.5)                 244 (4.7)                 96 (9.8)                  19.8
  Psychoses                                             247 (4)                   192 (3.7)                 55 (5.6)                  9.1
  Depression                                            637 (10.3)                523 (10.1)                114 (11.7)                5
  Early treatments/procedures (day 0, 1, or 2)                                                                                        
  ICU/CVICU/intermediate care                           3940 (64)                 3380 (65.3)               560 (57.3)                16.5
  Vasodilators                                          2537 (41.2)               2182 (42.1)               355 (36.3)                12
  NIV                                                   357 (5.8)                 312 (6)                   45 (4.6)                  6.4
  IMV                                                   2650 (43.1)               2403 (46.4)               247 (25.3)                45.3
  Vasopressors                                          2636 (42.8)               2379 (46)                 257 (26.3)                41.9
  Arterial line                                         701 (11.4)                627 (12.1)                74 (7.6)                  15.3
  IABP                                                  392 (6.4)                 357 (6.9)                 35 (3.6)                  14.9
  Inotropes                                             1281 (20.8)               1180 (22.8)               101 (10.3)                34
  Hospital size, beds                                                                                                                 4.5
  ≤200                                                  327 (5.3)                 282 (5.4)                 45 (4.6)                  
  201--400                                              1866 (30.3)               1559 (30.1)               307 (31.4)                
  ≥401                                                  3962 (64.4)               3336 (64.4)               626 (64)                  
  Rural/urban                                                                                                                         3.9
  Urban                                                 5346 (86.9)               4503 (87.0)               843 (86.2)                
  Rural                                                 809 (13.1)                674 (13.0)                135 (13.8)                
  Hospital region                                                                                                                     17.3
  Northeast                                             886 (14.4)                725 (14.0)                161 (16.5)                
  Midwest                                               1048 (17.0)               930 (18.0)                118 (12.1)                
  West                                                  384 (6.2)                 326 (6.3)                 58 (5.9)                  
  South                                                 3837 (62.3)               3196 (61.7)               641 (65.5)                
  Teaching status                                                                                                                     16.6
  Nonteaching                                           2831 (46.0)               2351 (45.4)               480 (49.1)                
  Teaching                                              3324 (54.0)               2826 (54.6)               498 (50.9)                
  Outcomes---CABG Group                                                                                                               GEE *P* Value[a](#jah33446-note-0003){ref-type="fn"}
  In‐hospital mortality                                 103 (1.7)                 92 (1.8)                  11 (1.1)                  0.14
  LOS, d                                                                                                                              
  Median (IQR)                                          8 (6--11)                 8 (6--11)                 9 (7--12)                 
  Mean (SD)                                             9.6 (6.3)                 9.5 (6.5)                 10.4 (5.4)                
  Winsorized at 99th percentile, mean (SD)              9.2 (4.4)                 9.0 (4.4)                 10.0 (4.3)                \<0.001
  Winsorized at 99th percentile, survivors, mean (SD)   9.2 (4.3)                 9.0 (4.3)                 10 (4.3)                  
  All‐cause readmission among survivors (≈1 mo)         700 (11.6)                579 (11.4)                121 (12.5)                0.2
  Cost, US \$                                                                                                                         
  Median (IQR)                                          35 414 (27 944--47 363)   35 058 (27 222--47 410)   36 603 (29 229--47 254)   
  Mean (SD)                                             41 327 (25 034)           41 349 (25 879)           41 210 (19 990)           
  Winsorized at 1st and 99th percentiles, mean (SD)     40 768 (20 812)           40 726 (21 238)           40 996 (18 403)           0.56

  Description                                           Medical MI                                                        
  ----------------------------------------------------- --------------------- --------------------- --------------------- ------------------------------------------------------
  Patients                                              4519 (100)            3681 (81.5)           838 (18.5)            
  Age, y                                                                                                                  
  Median (IQR)                                          61 (53--69)           61 (53--70)           60 (52--67)           
  Mean (SD)                                             61.0 (12.6)           61.3 (12.9)           60.0 (11.4)           11
  Sex                                                                                                                     
  Male                                                  2725 (60.3)           2211 (60.1)           514 (61.3)            
  Female                                                1794 (39.7)           1470 (39.9)           324 (38.7)            2.6
  Race/ethnicity                                                                                                          15.7
  White                                                 3089 (68.4)           2468 (67)             621 (74.1)            
  Black                                                 779 (17.2)            657 (17.8)            122 (14.6)            
  Hispanic                                              179 (4)               152 (4.1)             27 (3.2)              
  Other                                                 472 (10.4)            404 (11)              68 (8.1)              
  Marital status                                                                                                          8.1
  Married                                               1664 (36.8)           1358 (36.9)           306 (36.5)            
  Single                                                2372 (52.5)           1914 (52)             458 (54.7)            
  Other                                                 483 (10.7)            409 (11.1)            74 (8.8)              
  Insurance payer                                                                                                         11.3
  Medicare                                              2334 (51.6)           1906 (51.8)           428 (51.1)            
  Medicaid                                              744 (16.5)            593 (16.1)            151 (18)              
  Managed care                                          704 (15.6)            582 (15.8)            122 (14.6)            
  Commercial‐indemnity                                  194 (4.3)             149 (4)               45 (5.4)              
  Self‐pay                                              318 (7)               257 (7)               61 (7.3)              
  Other                                                 225 (5)               194 (5.3)             31 (3.7)              
  Gagne combined comorbidity score                                                                                        
  Median (IQR)                                          2 (0--5)              2 (0--5)              2 (1--4)              
  Mean (SD)                                             2.7 (2.8)             2.8 (2.8)             2.7 (2.7)             4.7
  Comorbidities                                                                                                           
  Congestive heart failure                              1823 (40.3)           1518 (41.2)           305 (36.4)            10
  Valvular disease                                      733 (16.2)            616 (16.7)            117 (14)              7.7
  Pulmonary circulation disease                         361 (8)               291 (7.9)             70 (8.4)              1.6
  Peripheral vascular disease                           912 (20.2)            746 (20.3)            166 (19.8)            1.1
  Hypertension with complications                       1220 (27)             1025 (27.8)           195 (23.3)            10.5
  Hypertension without complications                    2408 (53.3)           1937 (52.6)           471 (56.2)            7.2
  Paralysis                                             95 (2.1)              83 (2.3)              12 (1.4)              6.1
  Other neurological disorders                          363 (8)               298 (8.1)             65 (7.8)              1.3
  Chronic pulmonary disease                             2074 (45.9)           1629 (44.3)           445 (53.1)            17.8
  Diabetes mellitus                                     1684 (37.3)           1408 (38.3)           276 (32.9)            11.1
  Hypothyroidism                                        398 (8.8)             326 (8.9)             72 (8.6)              0.9
  Renal failure                                         998 (22.1)            854 (23.2)            144 (17.2)            15
  Liver disease                                         187 (4.1)             154 (4.2)             33 (3.9)              1.2
  AIDS                                                  8 (0.2)               8 (0.2)                                     6.6
  Lymphoma                                              17 (0.4)              16 (0.4)              1 (0.1)               6
  Metastatic cancer                                     61 (1.3)              51 (1.4)              10 (1.2)              1.7
  Solid tumor without metastasis                        99 (2.2)              87 (2.4)              12 (1.4)              6.8
  Rheumatoid arthritis/collagen vascular                112 (2.5)             96 (2.6)              16 (1.9)              4.7
  Obesity                                               797 (17.6)            659 (17.9)            138 (16.5)            3.8
  Weight loss                                           229 (5.1)             183 (5)               46 (5.5)              2.3
  Chronic blood loss anemia                             44 (1)                40 (1.1)              4 (0.5)               6.9
  Deficiency anemias                                    866 (19.2)            721 (19.6)            145 (17.3)            5.9
  Alcohol abuse                                         483 (10.7)            338 (9.2)             145 (17.3)            24.1
  Drug abuse                                            481 (10.6)            379 (10.3)            102 (12.2)            5.9
  Psychoses                                             279 (6.2)             212 (5.8)             67 (8)                8.8
  Depression                                            610 (13.5)            478 (13)              132 (15.8)            7.9
  Early treatments/procedures (day 0, 1, or 2)                                                                            
  ICU/CVICU/intermediate care                           2009 (44.5)           1663 (45.2)           346 (41.3)            7.9
  Vasodilators                                          1031 (22.8)           845 (23)              186 (22.2)            1.8
  NIV                                                   329 (7.3)             273 (7.4)             56 (6.7)              2.9
  IMV                                                   314 (6.9)             281 (7.6)             33 (3.9)              15.9
  Vasopressors                                          318 (7)               288 (7.8)             30 (3.6)              18.4
  Arterial line                                         43 (1)                35 (1)                8 (1)                 0
  IABP                                                  51 (1.1)              43 (1.2)              8 (1)                 2.1
  Inotropes                                             164 (3.6)             153 (4.2)             11 (1.3)              17.5
  Hospital size, beds                                                                                                     6.5
  ≤200                                                  380 (8.4)             313 (8.5)             67 (8)                
  201--400                                              1611 (35.6)           1291 (35.1)           320 (38.2)            
  ≥401                                                  2528 (55.9)           2077 (56.4)           451 (53.8)            
  Rural/urban                                                                                                             1.9
  Urban                                                 3785 (83.8)           3105 (84.3)           680 (81.1)            
  Rural                                                 734 (16.2)            576 (15.6)            158 (18.8)            
  Hospital region                                                                                                         6.8
  Northeast                                             634 (14.0)            510 (13.8)            124 (14.8)            
  Midwest                                               869 (19.2)            720 (19.6)            149 (17.8)            
  West                                                  268 (5.9)             225 (6.1)             43 (5.1)              
  South                                                 2748 (60.8)           2226 (60.5)           522 (62.3)            
  Teaching status                                                                                                         4.6
  Nonteaching                                           2117 (46.8)           1696 (46.1)           421 (50.2)            
  Teaching                                              2402 (53.1)           1985 (53.9)           417 (49.8)            
  Outcomes---Medical MI                                                                                                   GEE *P* Value[a](#jah33446-note-0003){ref-type="fn"}
  In‐hospital mortality                                 189 (4.2)             169 (4.6)             20 (2.4)              0.005
  LOS, d                                                                                                                  
  Median (IQR)                                          3 (2--5)              3 (2--6)              3 (2--5)              
  Mean (SD)                                             4.8 (4.5)             4.8 (4.6)             4.4 (3.8)             
  Winsorized at 99th percentile, mean (SD)              4.7 (3.8)             4.7 (3.9)             4.4 (3.5)             0.02
  Winsorized at 99th percentile, survivors, mean (SD)   4.6 (3.7)             4.7 (3.8)             4.3 (3.4)             
  All‐cause readmission among survivors (≈1 mo)         686 (15.8)            560 (15.9)            126 (15.4)            0.57
  Cost, US \$                                                                                                             
  Median (IQR)                                          8491 (5821--13 303)   8586 (5822--13 721)   8154 (5815--11 822)   
  Mean (SD)                                             12 162 (13 399)       12 497 (13 915)       10 691 (10 726)       
  Winsorized at 1st and 99th percentiles                11 807 (10 504)       12 113 (10 837)       10 464 (8776)         0.0005

CABG indicates coronary artery bypass graft; CVICU, cardiovascular ICU; GEE, generalized estimating equation; IABP, intra‐aortic balloon pump; ICU, intensive cardiac unit; IMV, invasive mechanical ventilation; IQR, interquartile range; LOS, length of stay; MI, myocardial infarction; NIV, noninvasive ventilation; NRT, nicotine replacement therapy; PCI, percutaneous coronary intervention; PCIMI, PCI with or without MI.

Accounting for patient clustering within hospitals using GEE.

Our primary analysis evaluated the independent association of NRT with outcomes in a propensity‐matched cohort. Within each patient diagnosis group, we developed a hierarchical nonparsimonious propensity model with a random intercept for the hospital to predict receipt of NRT. These models included every defined and reported variable, which included patient demographics, comorbidities, early critical care therapies, hospital characteristics, and significant interactions between all factors.[26](#jah33446-bib-0026){ref-type="ref"} We then used a greedy match algorithm to pair each treated patient with a patient who did not receive NRT with similar propensity score[24](#jah33446-bib-0024){ref-type="ref"} and assessed balance between the matched samples using absolute standardized differences. We then used multivariable conditional logistic regression models for inpatient mortality and 1‐month readmission outcomes in the matched cohort. For LOS and cost, we used identity link models. All models accounted for the propensity match. Among the medically managed MI group, we also adjusted for the few residual imbalanced factors between groups after propensity matching. Analyses were performed using SAS, version 9.4 (SAS Institute, Inc, Cary, NC) and STATA (StataCorp 2013; Stata Statistical Software: Release 13; StataCorp LP, College Station, TX).

Results {#jah33446-sec-0015}
=======

We identified 36 675 admissions for smokers admitted with medically managed MI, PCI±MI, or CABG. After exclusions, we evaluated a total of 27 459 unique admissions for unique smokers from 270 hospitals (Figure [1](#jah33446-fig-0001){ref-type="fig"}). Of these individuals, 4885 (17.8%) received some form of NRT in the first 2 days of hospitalization. The most common prescription was the nicotine patch (17.6% of patients) at a median daily dose of 21 mg/d for a median of 3 days. Before matching, baseline characteristics in all 3 patient groups showed multiple, clinically significant differences across treatment categories. When compared with patients without NRT, patients who received NRT were generally younger, were more likely to be white, and had higher rates of complicated hypertension, chronic obstructive pulmonary disease, drug use, and alcohol use (Table [1](#jah33446-tbl-0001){ref-type="table"}). There were also differences in unadjusted outcomes (Table [1](#jah33446-tbl-0001){ref-type="table"}), which changed only minimally when patients with late‐start NRT were included in the control group (Table [2](#jah33446-tbl-0002){ref-type="table"}).

![Patient selection flow chart. CABG indicates coronary artery bypass graft; MI, myocardial infarction; NRT, nicotine replacement therapy; PCI, percutaneous coronary intervention; PCIMI, PCI with or without MI.](JAH3-7-e009424-g001){#jah33446-fig-0001}

###### 

Unadjusted Outcomes When Including Late NRT Starts in the Control Group

  Description                                                     PCIMI                     CABG                      Medical MI                                                                
  --------------------------------------------------------------- ------------------------- ------------------------- ------------------------- ------------------------- --------------------- ---------------------
  In‐hospital mortality, n (%)                                    242 (1.7)                 15 (0.5)                  98 (1.7)                  11 (1.1)                  172 (4.4)             20 (2.4)
  LOS, median (IQR), d[a](#jah33446-note-0005){ref-type="fn"}     3 (2--4)                  3 (2--4)                  8 (6--11)                 9 (7--12)                 3 (2--6)              3 (2--5)
  All‐cause readmission among survivors (≈1 mo), n (%)            1289 (9.1)                287 (9.4)                 621 (11.3)                121 (12.6)                575 (15.6)            124 (15.2)
  Cost, median (IQR), \$[b](#jah33446-note-0006){ref-type="fn"}   14 936 (11 318--20 976)   14 493 (11 355--19 136)   35 363 (27 427--47 784)   36 653 (29 301--47 318)   8746 (5913--13 980)   8210 (5826--12 011)

CABG indicates coronary artery bypass graft; IQR, interquartile range; LOS, length of stay; MI, myocardial infarction; NRT, nicotine replacement therapy; PCIMI, percutaneous coronary intervention with or without MI.

Measure winsorized at 99th percentile.

Measure winsorized at 1st and 99th percentiles.

The distributions of propensity scores with overlap between groups are shown in Figure [2](#jah33446-fig-0002){ref-type="fig"}. For patients with medically managed MI, PCI±MI, and CABG, the areas under the receiver operating curve to distinguish likelihood of NRT receipt were 0.762, 0.740, and 0.816, respectively, for each propensity score. We successfully matched 91.8%, 91.2%, and 96.9%, respectively, of the patients who were treated with NRT to those not treated for a total of 769, 2975, and 892 matched pairs for each patient group, respectively (Figure [1](#jah33446-fig-0001){ref-type="fig"}).

![Propensity score distributions and overlap by receipt of nicotine replacement therapy (NRT) by patient group. CABG indicates coronary artery bypass graft; MI, myocardial infarction; PCIMI, percutaneous coronary intervention with or without MI.](JAH3-7-e009424-g002){#jah33446-fig-0002}

Patient characteristics after matching are shown in Table [3](#jah33446-tbl-0003){ref-type="table"}. In general, the mean age ranged from 56 to 60 years, with 59% to 75% men, and 75% to 79% white, depending on the group. After matching, all covariates were well balanced, with absolute standardized differences of \<10% among all groups, suggesting mostly similar baseline characteristics, except among patients with medically managed MI. These patients had persistent baseline differences in the frequency of pulmonary circulation disorders, hypertension with complications, and renal failure, but in all 3 of these comorbidities there was a higher prevalence of these disorders among patients treated with NRT.

###### 

Patient Characteristics in Propensity‐Matched Cohorts

  Characteristics                                           PCIMI         CABG        Medical MI                                                               
  --------------------------------------------------------- ------------- ----------- ------------ ------------ ------------ ----- ------------- ------------- ------
  Patients, n (%)                                           2975 (50)     2975 (50)                892 (50)     892 (50)           769 (50)      769 (50)      
  Group                                                                                                                                                        
  PCI                                                       26.4          25.9                                                                                 
  MI+PCI                                                    73.6          74.1        1.1                                                                      
  Age, mean (SD), y                                         56.1 (10.3)   56 (9.8)    1            58.4 (9.5)   58.2 (9.2)   2.1   60.2 (12.4)   60.2 (11.6)   0.1
  Female sex                                                30.7          31.5        1.9          25.3         24.4         2.1   41.7          39.9          3.7
  Race/ethnicity                                                                      5.3                                    1.4                               6.6
  White                                                     79.4          77.3                     79.6         79.4               76.5          74            
  Black                                                     8.2           8.8                      5.8          5.9                13.4          14.2          
  Hispanic                                                  2.8           3.2                      2.9          3.1                3             3.1           
  Other                                                     9.6           10.7                     11.7         11.5               7.2           8.7           
  Marital status                                                                      4.4                                    4                                 8.6
  Married                                                   44            41.9                     47.5         47.1               41.1          37.1          
  Single                                                    46.2          47.5                     44.5         43.8               51.2          54.1          
  Other                                                     9.8           10.6                     8            9.1                7.7           8.8           
  Insurance payer                                                                     4.2                                    4.9                               4.9
  Medicare                                                  29.6          30.2                     36           37.1               49.9          51.9          
  Medicaid                                                  21.2          20.1                     21.3         20.5               17.8          17.6          
  Managed care                                              25.9          26.7                     21.1         21.7               15.6          15.1          
  Commercial‐indemnity                                      5.9           5.8                      8.6          7.7                4.7           4.7           
  Self‐pay                                                  12.4          11.8                     7.3          7.6                8.1           7             
  Other                                                     4.9           5.4                      5.7          5.3                3.9           3.8           
  Gagne combined comorbidity score, mean (SD)               1 (2.1)       1.1 (2.1)   0.7          2.4 (2.5)    2.3 (2.5)    2.9   2.5 (2.6)     2.7 (2.7)     4.7
  Comorbidities                                                                                                                                                
  Congestive heart failure                                  18            19.1        2.9          26           27.1         2.5   38.5          37.1          3
  Valvular disease                                          8.1           7.9         1            16.1         16.7         1.5   12.1          14.4          6.9
  Peripheral vascular disease                               12.1          12.9        2.4          23.1         23.4         0.8   18.1          20.8          6.9
  Hypertension with complications                           9.4           10.7        4.2          17.3         15.4         5.2   18.5          23.8          13.1
  Hypertension without complications                        63.5          62.1        3.1          66.6         68.9         5     58.4          56            4.7
  Chronic pulmonary disease                                 35            33.8        2.6          56.6         54.7         3.8   53.8          52.8          2.1
  Diabetes mellitus                                         29.6          30.1        1            41.9         42.4         0.9   30.8          33.8          6.4
  Renal failure                                             6.5           6.8         1.4          13.5         11.8         5.1   14.2          17.9          10.3
  Obesity                                                   20.8          19.3        4            24.2         23.8         1.1   17.4          16.4          2.8
  Deficiency anemias                                        7             7.2         0.5          18.5         19.8         3.4   17.4          17.4          0
  Alcohol abuse                                             9.7           9.1         2.1          12.6         11.8         2.4   16.3          12.9          9.6
  Drug abuse                                                8.7           7.9         2.8          9.5          8.4          3.9   10            11.4          4.6
  Depression                                                12.5          11.5        3.1          11.3         10.9         1.4   15.1          16            2.5
  Early treatments[a](#jah33446-note-0008){ref-type="fn"}                                                                                                      
  ICU/intermediate care                                     56.2          55.1        1.1          59.3         57.4         3.9   40.6          41.2          1.3
  Vasodilators                                              41.8          39.1        3.3          36           36.9         1.9   23.3          22.2          2.5
  NIV                                                       3.4           3.2         1.4          4            4.7          3.3   6.4           7             2.6
  IMV                                                       2.8           3.4         0.6          26.1         27.2         2.5   3.5           4.3           4
  Vasopressors                                              9.7           9.3         0            27.5         27.7         0.5   4.4           3.8           3.3
  Arterial line                                             1.1           1.1         2            7.7          8            0.8   0.8           1             2.7
  IABP                                                      1.5           1.5         5.6          3            3.9          4.9   0.9           0.8           1.4
  Inotropes                                                 2.8           3.2         2.1          10.3         11.2         2.9   1             1.4           3.5
  Hospital size, beds                                                                 1.4                                    3.6                               0.8
  ≤200                                                      11.1          10.8                     4.7          4.4                7.8           7.9           
  201--400                                                  38.1          37.8                     32.3         30.9               37.7          38            
  ≥401                                                      50.8          51.4                     63           64.7               54.5          54.1          
  Hospital region                                                                     3.4                                    2.6                               8.7
  Northeast                                                 16.2          17                       16.4         16.8               13.3          15.1          
  Midwest                                                   21.4          20.2                     12.1         12.8               16.2          17.9          
  West                                                      6.2           6.5                      5.9          5.8                4.5           5.2           
  South                                                     56.2          56.3                     65.6         64.6               65.9          61.8          
  Urban hospital                                            81.6          82.3        1.1          86.2         86.3         1.6   81.9          81.9          0.5
  Teaching hospital                                         45.4          45.6        2.8          52.8         52.3         2     53.8          50.7          4.5

Data are given as percentage of each group unless otherwise indicated. ASDs are the ratio between the absolute differences in means of the 2 populations divided by mean variance of the total population. When sample sizes are large, ASDs are preferred to *P* values because *P* values are commonly \<0.05 because of high statistical power, without necessarily being reflective of important clinical differences. ASD values \>10% are generally considered clinically important (≈7% nonoverlap) between populations. ASD indicates absolute standardized difference; CABG, coronary artery bypass graft; IABP, intra‐aortic balloon pump; ICU, intensive care unit; IMV, invasive mechanical ventilation; MI, myocardial infarction; NIV, noninvasive ventilation; NRT, nicotine replacement therapy; PCI, percutaneous coronary intervention; PCIMI, PCI with or without MI.

Treatment on day 0, 1, or 2.

Outcomes are shown in Table [4](#jah33446-tbl-0004){ref-type="table"} for all 3 propensity‐matched patient groups. Overall, depending on subgroup, in‐hospital mortality ranged from 0.5% to 2.3%, mean hospital LOS ranged from 3.5 to 10 days, 1‐month readmission ranged from 8.9% to 15.8%, and cost ranged from \$10 428 to \$42 118. Unadjusted models show significantly lower overall mortality, hospital LOS, readmission, and total costs for patients treated with NRT (Table [1](#jah33446-tbl-0001){ref-type="table"}). However, in the propensity‐matched cohort, we found no differences in any outcomes in all 3 patient groups for patients treated versus not treated with NRT (Table [4](#jah33446-tbl-0004){ref-type="table"} and Figure [3](#jah33446-fig-0003){ref-type="fig"}).

###### 

Outcomes in Propensity‐Matched Cohorts by Diagnosis and Use of NRT

  Variable                                                        PCIMI             CABG            Medical MI                                                                               
  --------------------------------------------------------------- ----------------- --------------- ------------ ----------------- ----------------- ------- --------------- --------------- ------
  Patients, n (%)                                                 2975 (50)         2975 (50)                    892 (50)          892 (50)                  769 (50)        769 (50)        
  In‐hospital mortality, n (%)                                    26 (0.9)          14 (0.5)        0.06         20 (2.2)          11 (1.2)          0.099   16 (2.1)        18 (2.3)        0.98
  LOS, mean (SD), d[c](#jah33446-note-0012){ref-type="fn"}        3.5 (2.7)         3.6 (2.6)       0.91         9.6 (4.5)         10.0 (4.4)        0.06    4.3 (3.3)       4.4 (3.5)       0.60
  All‐cause readmission among survivors (≈1 mo), n (%)            289 (9.8)         263 (8.9)       0.22         91 (10.4)         111 (12.6)        0.16    119 (15.8)      110 (14.6)      0.31
  Cost, mean (SD), US \$[d](#jah33446-note-0013){ref-type="fn"}   17 243 (10 475)   17 085 (9855)   0.55         42 118 (23 111)   41 078 (18 529)   0.28    10 502 (8731)   10 428 (8814)   0.57

CABG indicates coronary artery bypass graft; LOS, length of stay; MI, myocardial infarction; NRT, nicotine replacement therapy; PCIMI, percutaneous coronary intervention with or without MI.

Accounting for propensity match.

Accounting for propensity match and adjustment for imbalanced factors.

Measure winsorized at 99th percentile (number \[percentage\] of patients affected: PCI, 145 \[0.9%\]; CABG, 60 \[1%\]; medical MI, 37 \[0.8%\]).

Measure winsorized at 1st and 99th percentiles (number \[percentage\] of patients affected: PCI, 197 \[1.1%\] and 167 \[1%\]; CABG, 67 \[1.1%\] and 61 \[1%\]; medical MI, 51 \[1.1%\] and 45 \[1%\], respectively).

![Odds ratios for mortality and 1‐month all‐cause readmission for each group in propensity‐matched cohort. All models account for propensity match. Models for medical myocardial infarction (MI) group are further adjusted for unbalanced factors. CABG indicates coronary artery bypass graft; NRT, nicotine replacement therapy; PCIMI, percutaneous coronary intervention with or without MI.](JAH3-7-e009424-g003){#jah33446-fig-0003}

Discussion {#jah33446-sec-0016}
==========

In this large pharmacoepidemiologic study of US smokers hospitalized with acute CHD, using robust analytic techniques and high statistical power, we found that starting NRT in the first 2 days of the hospitalization was not associated with any significant change in inpatient mortality, hospital LOS, readmission, or hospital costs. These findings were consistent across clinically diverse groups, including those with MI and those who underwent CABG or PCI. In addition, more than half of the population received care in an intensive care unit, \>25% of patients undergoing CABG remained intubated postoperatively, and a sizable portion (in all patient groups) required vasopressors, vasodilators, inotropes, and/or mechanical circulatory support. Despite a high level of acuity, MI among many patients, and possible hemodynamic instability, the use of NRT products starting during the first 2 days of hospitalization was not associated with any significant differences (harm or benefit) in outcomes among smokers hospitalized with acute CHD.

This study provides the strongest data available to address clinical uncertainty about the safety of NRT when used as a replacement for smokers hospitalized with acute MI or for treatment of CHD. The uncertainty stems from an absence of randomized controlled trials that included this specific population, in whom nicotine has a theoretical potential for causing harm because of its adrenergic and vasospastic properties. This is in contrast to the use of NRT in smokers with stable CHD seen in the outpatient setting, where randomized controlled trials have established NRT\'s safety.[2](#jah33446-bib-0002){ref-type="ref"}, [3](#jah33446-bib-0003){ref-type="ref"}, [4](#jah33446-bib-0004){ref-type="ref"} Although NRT has never clearly been associated with harm in the setting of acute CHD, prior concerns were extrapolated from physiologic data in nonsmokers, in short‐term pharmacologic and physiologic experimental settings, or in case reports or small case series, despite the potential pitfalls in using this kind of data to make clinical decisions. Instead, our well‐powered study joins the majority of observational and randomized trials that have demonstrated a lack of any association between NRT use and morbidity, including patients at hospital discharge for CAD, in the medical intensive care unit, and among the general population.[6](#jah33446-bib-0006){ref-type="ref"}, [7](#jah33446-bib-0007){ref-type="ref"}, [8](#jah33446-bib-0008){ref-type="ref"}, [27](#jah33446-bib-0027){ref-type="ref"} Furthermore, recent physiologic studies have called into question the universally held belief that NRT is consistently associated with an increase in blood pressure and heart rate, particularly when it is used to replace cigarette smoking during a short‐term hospitalization.[28](#jah33446-bib-0028){ref-type="ref"}, [29](#jah33446-bib-0029){ref-type="ref"} Although NRT does have minor adverse effects[30](#jah33446-bib-0030){ref-type="ref"} and some caution will always be appropriate, it appears that for the general population of smokers (both inpatient and outpatient), the use of NRT is unlikely to lead to important adverse cardiovascular effects.

We believe our findings have significant implications for tobacco treatment among patients hospitalized with CHD for several reasons. First, and most important, our findings suggest that physicians can prescribe NRT to alleviate nicotine withdrawal symptoms without concern for inducing adverse events. Although nicotine withdrawal is underrecognized in the hospital, nicotine withdrawal is common, peaks within 1 week of smoking cessation, and includes symptoms of irritability, anxiety, difficulty concentrating, restlessness, and depressed mood.[31](#jah33446-bib-0031){ref-type="ref"} Because these symptoms are largely relieved with NRT, increased use of NRT should improve quality of care and patient experience for many smokers,[32](#jah33446-bib-0032){ref-type="ref"}, [33](#jah33446-bib-0033){ref-type="ref"}, [34](#jah33446-bib-0034){ref-type="ref"} and should also help avoid nicotine withdrawal‐associated delirium.[35](#jah33446-bib-0035){ref-type="ref"}, [36](#jah33446-bib-0036){ref-type="ref"} Second, because inpatient NRT use has been associated with greater outpatient NRT use[13](#jah33446-bib-0013){ref-type="ref"} and NRT is a well‐accepted and generally effective treatment for smoking cessation,[37](#jah33446-bib-0037){ref-type="ref"}, [38](#jah33446-bib-0038){ref-type="ref"} greater use of NRT in the inpatient setting should positively influence long‐term smoking cessation rates.[14](#jah33446-bib-0014){ref-type="ref"} Third, because the Joint Commission now considers prescription of pharmacotherapy for smoking cessation (of which the vast majority is NRT) a standard of care for both inpatient use and at hospital discharge,[39](#jah33446-bib-0039){ref-type="ref"} and patient motivation to quit smoking is high after a hospitalization, we believe that hospitals can pursue quality initiatives[40](#jah33446-bib-0040){ref-type="ref"} to ensure that all hospitalized smokers are offered and prescribed smoking cessation medications to improve smoking cessation outcomes and to meet Joint Commission performance measures. Fourth, we believe that there is now enough combined evidence that guideline writers should consider adding statements about the lack of harm with NRT in smokers with acute CHD.

Strengths of this study include its large size, geographic diversity, high acuity population, and use of robust statistical techniques with excellent covariate balance after propensity matching. These minimize concern for confounding. Nonetheless, as an observational study, it may have residual confounding because of important unmeasured covariates, which limits the causal inference that can be made. For example, NRT prescription at hospital discharge and NRT use at home were not available in Premier, but would be useful to understand the risk of NRT on readmission. In addition, usual smoking habits (cigarettes per day), dual tobacco product use, such as e‐cigarettes, and usual blood nicotine levels were not available and could have potentially influenced the dose of NRT that was prescribed by clinicians. If patients were consistently underdosed or overdosed, this could affect the safety of NRT in the short‐term setting. Future research would do well to explore issues related to NRT dose and safety. Last, because Premier only records the day of NRT administration, a more detailed analysis by hours of exposure was not possible. Thus, for inpatient mortality, it is possible that we excluded some patients with NRT‐related mortality if they died within the first 2 days. However, we think this is unlikely to be the case because unadjusted mortality among the 5296 patients excluded was 1.6% versus 6.2% for early NRT versus no NRT.

The other main limitation is that we were unable to examine smoking cessation outcomes and long‐term outcomes, such as 1‐year mortality, although we did evaluate 30‐day readmission. Similarly, we were unable to examine intermediate outcomes, like recurrent MI, or new‐onset hypertensive urgency, stroke, or arrhythmias that occurred after initiation of NRT. This occurred because *ICD‐9* codes do not have an associated date of onset, so it was not possible to determine if a stroke (for example) occurred before or after the administration of NRT. However, if these complications had occurred with any frequency as a result of NRT use, we believe such complications would have manifested themselves in difference in LOS or total hospital costs between groups, which were not seen in this study.

Although the prevalence of smoking is declining nationwide, it is important for clinicians to remember that smoking is still the leading cause of preventable death in the United States and is responsible for \>480 000 deaths per year.[41](#jah33446-bib-0041){ref-type="ref"} Smoking remains a critical risk factor for MI, with ≈50% of patients with ST‐segment--elevation MI being smokers.[42](#jah33446-bib-0042){ref-type="ref"} Although treatments such as NRT and varenicline are both readily available and effective,[14](#jah33446-bib-0014){ref-type="ref"}, [43](#jah33446-bib-0043){ref-type="ref"} they remain highly underused both during hospitalization and after discharge.[10](#jah33446-bib-0010){ref-type="ref"}, [44](#jah33446-bib-0044){ref-type="ref"} These findings suggest that physicians and hospitals have a large opportunity to improve the care of smokers with acute CHD.

Conclusions {#jah33446-sec-0017}
===========

For years, clinicians have worried about the potential toxicity of NRT in patients hospitalized with acute cardiac disease. Although a randomized trial would be the most definitive way to answer this question, our results should significantly reduce concerns about the safety of NRT among hospitalized patients with CHD. Further research should focus on identifying effective strategies that increase delivery of NRT and other smoking cessation therapies so that all smokers receive effective treatments to help them quit smoking permanently.
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